Treatment for Charcot-Marie-Tooth disease.

@article{Young2008TreatmentFC,
  title={Treatment for Charcot-Marie-Tooth disease.},
  author={Peter Young and Peter de Jonghe and Florian Stoegbauer and Trude Butterfass-Bahloul},
  journal={The Cochrane database of systematic reviews},
  year={2008},
  volume={1},
  pages={
          CD006052
        }
}
BACKGROUND Charcot-Marie-Tooth disease (CMT) comprises a large variety of different forms of motor and sensory neuropathies. The most frequent are demyelinating forms (CMT1) and axonal forms (CMT2). The molecular basis of several CMT forms has been clarified during the last 15 years. Since muscle wasting and sensory disturbance are the main features of these syndromes, treatments aim to improve motor impairment and sensory disturbances. Specific treatment trials are rare. OBJECTIVES The… CONTINUE READING
Highly Cited
This paper has 28 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

The effect of myelinating Schwann cells on axons.

Muscle & nerve • 2001
View 3 Excerpts
Highly Influenced

Quantitating overall neuropathic symptoms, impairments, and outcomes

PJ Dyck 2005b Dyck, RAC Hughes, PC. O’Brien
2005

The causes of Charcot-Marie-Tooth disease

Cellular and Molecular Life Sciences CMLS • 2003

Clinical features and molecular genetics of hereditary peripheral neuropathies

P Young, G Hunermund, B Ringelstein, F. Stogbauer
Kuhlenbaumer • 2002